Metal hip replacement manufacturer BioMet Inc. has partnered with orthopedic company OrthoSensor to promote its knee replacements, despite patients reporting problems with its M2a Magnum metal-on-metal hip replacement. The companies will market their products directly to surgeons.
Patients began complaining of complications relating to the BioMet M2a Magnum hip implant shortly after the device appeared on the market. The M2a Magnum was approved via the controversial 501(k) process, which allows a company to sell the device before substantial safety tastes can be conducted.
BioMet M2a Magnum complications include metallosis, hip pain and premature loosening of the hip implant. More than 7% of M2a hip replacements failed within the first year, requiring patients to undergo revision surgery to correct hip implant problems.